Antifungal and antiviral chemotherapy

Periodontology 2000

Volumn 28, Issue 1, 2002, Pages 240-255

  Pallasch, Thomas J ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; ANTIVIRUS AGENT; POLYENE; PYRROLE DERIVATIVE;

ANTIBIOTIC RESISTANCE; APHTHOUS STOMATITIS; CHEMISTRY; HUMAN; MOUTH DISEASE; MYCOSIS; RECURRENT DISEASE; REVIEW; STOMATITIS; THRUSH; VIRUS INFECTION;

ANTIFUNGAL AGENTS; ANTIVIRAL AGENTS; AZOLES; CANDIDIASIS, ORAL; DRUG RESISTANCE, FUNGAL; DRUG RESISTANCE, VIRAL; HUMANS; MOUTH DISEASES; MYCOSES; POLYENES; RECURRENCE; STOMATITIS, APHTHOUS; STOMATITIS, DENTURE; VIRUS DISEASES;

EID: 0036359123     PISSN: 09066713     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0757.2002.280110.x     Document Type: Article

References (87)

1. Albertson GD, Niimi M, Cannon RD, Jenkinson HF. Multiple efflux mechanisms are involved in Candida albicans fluconazole resistance. Antimicrob Agents Chemother 1996: 40: 2835-2841.
2. Andersson J. Clinical and immunological considerations in Epstein-Barr virus-associated diseases. Scand J Infect Dis 1996: S100: 72-82.
3. Appleton SS. Candidiasis: pathogenesis, clinical characteristics, and treatment. Calif Dent Assoc J 2000: 28: 942-948.
4. Arvin AM. Varicella-zoster virus. Clin Microbiol Rev 1996: 9: 361-381.
5. Ashley RL, Wald A. Genital herpes: review of the epidemic and potential use of type-specific serology. Clin Microbiol Rev 1999: 12: 1-8.
6. Balfour HH Jr. Prevention of cytomegalovirus disease. Int J Antimicrob Agents 1996: 7: 283-285.
7. Balfour HH Jr. Antiviral drugs. N Engl J Med 1999: 340: 1255-1268.
8. Benedetti J, Corey L, Ashley R. Recurrence rates in genital herpes after symptomatic first episode infection. Ann Intern Med 1994: 121: 847-854.
9. Birek C. Herpes virus-induced diseases: oral manifestations and current treatment options. Calif Dent Assoc J 2000: 28: 911-921.
10. Braun DK, Dominguez G, Pellett PE. Human herpesvirus 6. Clin Microbiol Rev 1997: 10: 521-567.
11. Chang Y, Cesarman E, Pessin MS, Lee F, Culpepper J, Knowles DM, Moore PS. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science 1994: 266: 1865-1869.
12. Chou S, Miner RC, Drew WL. A deletion mutation in region V of the cytomegalovirus DNA polymerase sequence confers multidrug resistance. J Infect Dis 2000: 182: 1765-1768.
13. Danner SA. Management of cytomegalovirus disease. AIDS 1995: 9: S3-S8.
14. DiDomenico B. Novel antifungal drugs. Curr Opin Microbiol 1999: 2: 509-515.
15. Dockerell DH, Smith TF, Paya CV. Human herpesvirus 6. Mayo Clin Proc 1999: 74: 163-170.
16. Drug facts and comparisons. 2000-2001. St. Louis: Facts and Comparisons, 2000.
17. Engel JP. Long-term suppression of genital herpes. JAMA 1998: 280: 928-929.
18. Epstein F, Scully C. Cytomegalovirus: a virus of increasing relevance to oral medicine and pathology. J Oral Pathol Med 1993: 22: 348-353.
19. Epstein JB, Sherlock CH, Wolber RA. Oral manifestations of cytomegalovirus infection. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1993: 75: 443-451.
20. Erice A. Resistance of human cytomegalovirus to antiviral drugs. Clin Microbiol Rev 1999: 12: 286-297.
21. Eversole LR. Inflammatory diseases of the mucous membranes. I. Viral and fungal infections. Calif Dent Assoc J 1994: 22: 52-57.
22. Fleming DT, McQuillan GM, Johnson RE, Nahmias AJ, Aral SO, Lee FK, St Louis ME. Herpes simplex virus type 2 in the United States, 1976-1994. N Engl J Med 1997: 337: 1105-1111.
23. Fostel JM, Lartey PA. Emerging novel antifungal agents. Drug Discovering Today 2000: 5: 25-32.
24. Ghannoum MA, Rice LB. Antifungal agents: mode of action, mechanisms of resistance and correlation of these mechanisms with bacterial resistance. Clin Microbiol Rev 1999: 12: 501-517.
25. Giuliana G, Pizzo G, Milici ME, Giangreco R. In vitro activities of antimicrobial agents against Candida species. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1999: 87: 44-49.
26. Glick M, Siegel MA. Viral and fungal infections of the oral cavity in immunocompetent patients. Infect Dis Clin North Am 1999: 13: 817-831.
27. Goldman M, Cloud GA, Smedema M, LeMonte A, Connolly P, McKinsey DS, Kauffman CA, Moskovitz B, Wheat LJ. Does long-term itraconazole prophylaxis result in in vitro azole resistance in mucosal Candida albicans isolates from persons with advanced human immunodeficiency virus infection? Antimicrob Agents Chemother 2000: 44: 1585-1587.
28. Graykowski EA, Kingman A. Double-blind trial of tetracycline in recurrent aphthous ulceration. J Oral Pathol 1978: 7: 376-378.
29. Griffiths P. The herpesvirus family in the 21st century. Antiviral Chem Chemother 1997: 8(S1): 11-15.
30. Griffiths PD, Clark DA, Emery VC. Betaherpesviruses in transplant recipients. J Antimicrob Chemother 2000: 45: 29-34.
31. Grint PCA, Ronalds CJ, Kangro HO, Campbell-Benzie A, Ward F, Hardiman AE, Heath RB. Screening tests for antibodies to cytomegalovirus: an evaluation of five commercial products. J Clin Pathol 1985: 38: 1059-1064.
32. Hamprecht K, Maschmann J, Vochem M, Dietz K, Speer CP, Jahn G. Epidemiology of transmission of cytomegalovirus from mother to preterm infant by breastfeeding. Lancet 2001: 357: 513-518.
33. Hamuy R, Berman B. Treatment of herpes simplex virus infections with topical antiviral agents. Eur J Dermatol 1998: 8: 310-319.
34. Hayden FG. Antiviral drugs (other than antiretrovirals). In: Mandell GL, Bennett JE, Dolin R, ed. Principles and practice of infectious diseases. 5th edn. Philadelphia: Churchill Livingstone, 2000.
35. Hearne K, Cirelli R, Lee P, Tyring SK. Antiviral therapy of acute herpes zoster in older patients. Drugs Aging 1996: 8: 97-112.
36. Hodinka RL. What clinicians need to know about antiviral drugs and viral resistance. Infect Dis Clin North Am 1997: 11: 945-967.
37. Jacobsen JM, Greenspan JS, Spritzer J, Fox L, Fahey JL, Jackson JB, Chernoff M, Wohl DA, Pulvirenti JJ, Hooton TM, Shikuma C, the National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group. Thalidomide in low intermittent doses does not prevent recurrence of human immunodeficiency virus-associated aphthous ulcers. J Infect Dis 2001: 183: 343-346.
38. Jacobsen PL, Yao S. Antifungal agents and modern antifungal therapy in dentistry. Calif Dent Assoc J 1993: 21: 44-53.
39. Jeganathan S, Lin CC. Denture stomatitis - a review of the aetiology, diagnosis and management. Aust Dent J 1992: 37: 107-114.
40. Jones AC, Freedman PD, Phelan JA, Baughman RA, Kerpel SM. Cytomegalovirus infections of the oral cavity: a report of six cases and a review of the literature. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1993: 22: 348-353.
41. Kakeya H, Miyazaki Y, Miyazaki H, Nyswaner K, Grimberg B, Bennett JE. Genetic analysis of azole resistance in the Darlington strain of Candida albicans. Antimicrob Agents Chemother 2000: 44: 2985-2990.
42. Kauffman CA, Carver PL. Antifungal agents in the 1990s. Current status and future developments. Drugs 1997: 53: 539-549.
43. Keating MR. Antiviral agents for non-human immunodeficiency virus infections. Mayo Clin Proc 1999: 74: 1266-1283.
44. Kimberlin DW, Wittley RJ. Human herpesvirus-6: neurological implications of a newly-described viral pathogen. J Neurovirol 1998: 4: 474-485.
45. Knopf CW. Molecular mechanisms of replication of herpes simplex virus 1. Acta Virol 2000: 44: 289-307.
46. Koelle DM, Wald A. Herpes simplex virus: the importance of asymptomatic shedding. J Antimicrob Chemother 2000: 45: 1-8.
47. Law D, Moore CB, Wardle HM, Ganguli LA, Keaney MG, Denning DW. High prevalence of antifungal resistance in Candida spp from patients with AIDS. J Antimicrob Chemother 1994: 34: 659-668.
48. Lucht E, Betting M, Bjerregaard L, Julander I, Linde A. Shedding of cytomegalovirus and herpesviruses 6, 7 and 8 in saliva from human immunodeficiency virus type-1 infected patients and healthy controls. Clin Infect Dis 1998: 27: 137-141.
49. Maenza JR, Merz WG, Romagnoli MJ, Kervly JC, Moore RD, Gallant JE. Infection due to fluconazole-resistant Candida in patients with AIDS: prevalence and microbiology. Clin Infect Dis 1997: 24: 28-34.
50. Maertens JA, Boogaerts MA. Fungal cell wall inhibitors: emphasis on clinical aspects. Curr Pharmaceut Design 2000: 6: 225-239.
51. Marley J. Antiviral therapy in herpes zoster: a review. Antiviral Chem Chemother 1997: 8(S1): 37-42.
52. Martin JN, Ganem DE, Osmund DH, Page-Shafer KA, Macrae D, Kedes DH. Sexual transmission and the natural history of human herpesvrus 8 infection. N Engl J Med 1998: 338: 948-954.
53. Martins MD, LozanoChiu M, Rex JH. Point prevalence of oropharyngeal carriage of fluconazole-resistant Candida in human immunodeficiency virus-infected patients. Clin Infect Dis 1997: 25: 843-846.
54. McMinn P, Stratov I, Nagarajan L, Davis S. Neurological manifestations of enterovirus 71 infection in children during an outbreak of hand, foot and mouth disease in Western Australia. Clin Infect Dis 2001: 32: 236-242.
55. Muzyka BC, Glick M. A review of oral fungal infections and appropriate therapy. J Am Dent Assoc 1995: 126: 63-72.
56. Nathwani D. Treatment parameters for the successful management of varicella zoster virus. Antimicrob Agents Chemother 1995: 6(S1): 12-16.
57. Pallasch TJ. Global antibiotic resistance and its impact on the dental community. Calif Dent Assoc J 2000: 28: 215-233.
58. Pedersen A. Psychological stress and recurrent aphthous ulcerations. J Oral Pathol Med 1989: 18: 119-122.
59. Pereira FA. Herpes simplex: evolving concepts. J Am Acad Dermatol 1996: 35: 503-520.
60. Pillay D, Zambon M. Antiviral drug resistance. BMJ 1998: 317: 660-662.
61. Regamey N, Tamm M, Wernli M, Thiel G, Cathomas G, Erb P. Transmission of human herpesvirus 8 infections from renal-transplant donors to recipients. N Engl J Med 1998: 339: 1358-1363.
62. Revankar SG, Kirkpatrick WR, McAtee RK, Dib OP, Fothergill AW, Redding SW, Rinaldi MG, Patterson TF. Detection and significance of fluconazole resistance in oropharyngeal candidiasis in human immunodeficiency virus-infected patients. J Infect Dis 1996: 174: 821-827.
63. Rosenberg SW, Arm RN. Clinician's guide to treatment of common oral conditions. 4th edn. Baltimore: American Academy of Oral Medicine, 1997.
64. Rotbart HA, Webster AD, the Pleconaril Treatment Registry Group. Treatment of potentially life-threatening enterovirus infections with pleconaril. Clin Infect Dis 2001: 32: 228-234.
65. Schmidt CW, Misko I. The ecology and pathology of Epstein-Barr virus. Immunol Cell Biol 1995: 73: 489-504.
66. Schulz TF. Kaposi's sarcoma-associated herpesvirus (human herpesvirus-8). J Gen Virol 1998: 79: 1573-1591.
67. Scott DDA, Coulter WA, Lamey PJ. Oral shedding of herpes simplex virus 1: a review. J Oral Pathol Med 1997: 26: 441-447.
68. Scully C, Porter SR. Recurrent aphthous stomatitis: current concepts of etiology, pathogenesis and management. J Oral Pathol Med 1989: 18: 21-27.
69. Scully C, Shotts R. Mouth ulcers and other causes of orofacial soreness and pain. BMJ 2000: 321: 162-165.
70. Shieh WJ, Jung S-M, Hsueh C, Kuo TT, Mounts A, Parashar U, Yang CF, Guarner J, Ksiazek TG, Dawson J, Goldsmith C, Chang GJ, Oberste SM, Pallansch MA, Anderson LJ, Zaki SR. Pathological studies of fatal cases in outbreak of hand, foot and mouth disease, Taiwan. Emerg Infect Dis 2001: 7: 146-148.
71. Ship JA. Recurrent aphthous stomatitis: an update. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1996: 81: 141-147.
72. Siegel MA. Strategies for management of commonly encountered oral mucosal disorders. Calif Dent Assoc J 1999: 27: 210-227.
73. Snoeck R, Andrei G, DeClerq E. Chemotherapy of varicella zoster virus infections. Int J Antimicrob Agents 1994: 4: 211-266.
74. Spruance SL. Prophylactic chemotherapy with acyclovir for recurrent herpes simplex labialis. J Med Virol 1993: S1: 27-32.
75. Spruance SL. Advances in the treatment of herpes simplex labialis. Antiviral Chem Chemother 1997: 8(S1): 69-74.
76. Sterling TR, Merz WC. Resistance to amphotericin B: emerging clinical and microbiological patterns. Drug Resist Updates 1998: 1: 161-165.
77. Stevens DA, Bennett IE. Antifungal agents. In: Mandell GL, Bennett JE, Dolin R, ed. Principles and practice of infectious diseases. 5th edn. Philadelphia: Churchill Livingstone, 2000.
78. Straus SE, Cohen JI, Tosato G, Meier I. Epstein-Barr virus infections: biology, pathogenesis and management. Ann Intern Med 1993: 118: 45-58.
79. Sugar AM. Antifungal combination therapy: where we stand. Drug Resist Update 1998: 1: 89-92.
80. Sugata T, Yoshinari M, Kyo T-I, Fujihara M. Oral aspergillosis in compromised patients. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1996: 81: 632-633.
81. Systemic antifungal drugs. Med Lett Drugs Ther 1996: 38: 10-12.
82. Terrell CL. Antifungal agents. II. The azoles. Mayo Clin Proc 1999: 74: 78-100.
83. Toscano CM, Jarvis WR. Emerging issues in nosocomial fungal infections. Curr Infect Dis Rep 1999: 1: 3247-361.
84. White TC, Marr KA, Bowden RA. Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. Clin Microbiol Rev 1998: 11: 382-402.
85. Whitley RJ, Lakeman E Herpes simplex virus infections of the central nervous system: therapeutic and diagnostic considerations. Clin Infect Dis 1995: 20: 414-420.
86. Whitley RJ, Kimberlin DW, Roizman B. Herpes simplex viruses. Clin Infect Dis 1998: 26: 541-555.
87. Woo S-B, Sonis ST. Recurrent aphthous ulcers: a review of diagnosis and treatment. J Am Dent Assoc 1996: 127: 1202-1213.